Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
View Patent ↗Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
1. A medical device comprising:
an implantable structure;
a basecoat matrix, including a combination of rapamycin and mycophenolic acid, in therapeutic dosages, incorporated in a first polymeric material, the basecoat matrix being affixed to the surface of the implantable medical device; and
a topcoat, including a second polymeric material, affixed to the basecoat matrix for controlling the elution rate of the rapamycin and mycophenolic acid, the first and second polymeric materials comprising immiscible polymers forming a chemical and physical barrier to the elution of the rapamycin and the mycophenolic acid, one of the immiscible polymers comprising a fluoropolymer and one of the immiscible polymers comprising an acrylic.
2. The medical device according to claim 1 , wherein the implantable structure comprises a stent.
3. The medical device according to claim 1 , wherein the implantable structure comprises a stent-graft.
4. The medical device according to claim 1 , wherein the implantable structure comprises an anastomosis device.
5. A medical device comprising:
an implantable structure;
a basecoat matrix, including mycophenolic acid, in therapeutic dosages, incorporated in a first polymeric matrix, the basecoat matrix being affixed to the surface of the implantable medical device; and
a topcoat, including a second polymeric material and rapamycin, in therapeutic dosages, affixed to the basecoat matrix for controlling the elution rate of the rapamycin and the mycophenolic acid, the first and second polymeric materials comprising immiscible polymers forming a chemical and physical barrier to the elution of the rapamycin and the mycophenolic acid, one of the immiscible polymers comprising a fluoropolymer and one of the immiscible polymers comprising an acrylic.